ACRX Share Price | Talphera, Inc. Stock Analysis & Recommendation

Q: How big is Talphera, Inc.?

Market Cap: As of Jun 18, Talphera, Inc. has a market capitalization of 9.74 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Talphera, Inc. reported net sales of 0.03 million and a net profit of -11.72 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 8.00 million, while total assets were reported at 18.24 million.

Q: What does Talphera, Inc. do?

Overview:Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) Market cap: USD 9.74 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.20 Return on Equity: -243.19% Price to Book: 1.74Contact Details:Address: 351 Galveston Dr, REDWOOD CITY CA: 94063-4736 Tel: 1 650 2163500 Fax: 1 650 2166500 Website: http://www.acelrx.com

Q: Is Talphera, Inc. overvalued or undervalued?

As of 8 November 2023, Talphera, Inc. has moved from a grade of risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently assessed as overvalued, particularly given its negative P/E ratio due to losses, a Price to Book Value of 1.87, and an alarming ROCE of -206.75%. The EV to EBITDA ratio stands at -0.83, further highlighting the company's struggles in generating earnings relative to its enterprise value.When compared to peers, Talphera's valuation metrics are concerning. For instance, Tonix Pharmaceuticals has a P/E of -3.669, while Iterum Therapeutics shows a P/E of -2.0489, both indicating worse performance in terms of profitability. Additionally, Talphera's stock has underperformed significantly against the S&P 500, with a year-to-date return of -16.05% compared to the index's 2.44%. This combination of negative financial ratios and poor stock performance suggests that Talphera, Inc. is indeed overvalued in the current market environment.

Q: Is Talphera, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Talphera, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. The Bollinger Bands also reflect a mildly bullish stance on the weekly chart and a bullish stance on the monthly chart. However, the daily moving averages are mildly bearish, suggesting some short-term weakness. The KST shows a bullish weekly signal but a bearish monthly signal, and the OBV is bullish on the monthly timeframe.In terms of performance, Talphera has had a strong one-month return of 115.77%, significantly outperforming the S&P 500's 2.33% return, but it has underperformed over longer periods, including a one-year return of 3.69% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven by the positive signals from the MACD and Bollinger Bands, despite some mixed signals from moving averages and KST.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

277.5 k

Shareholding (Sep 2025)

FII

9.65%

Held by 4 FIIs

DII

89.51%

Held by 2 DIIs

Promoter

0.01%

How big is Talphera, Inc.?

22-Jun-2025

As of Jun 18, Talphera, Inc. has a market capitalization of 9.74 million, with net sales of 0.03 million and a net profit of -11.72 million over the latest four quarters. The company's shareholder's funds are 8.00 million, and total assets are 18.24 million.

View full answer

What does Talphera, Inc. do?

22-Jun-2025

Talphera, Inc. is a micro-cap specialty pharmaceutical company focused on developing therapies for acute pain. As of March 2025, it reported net sales of $0 million and a net loss of $3 million, with a market cap of $9.74 million.

View full answer

Who are in the management team of Talphera, Inc.?

22-Jun-2025

As of March 2022, the management team of Talphera, Inc. includes Mr. Adrian Adams (Independent Chairman), Mr. Vincent Angotti (CEO), Dr. Pamela Palmer (Co-Founder and CMO), and several independent directors: Dr. Richard Afable, Mr. Mark Edwards, Dr. Stephen Hoffman, Mr. Howard Rosen, and Mr. Mark Wan. This team provides executive leadership and governance for the company.

View full answer

Is Talphera, Inc. overvalued or undervalued?

25-Jun-2025

As of November 8, 2023, Talphera, Inc. is considered overvalued due to its negative financial metrics, including a negative P/E ratio, a Price to Book Value of 1.87, a ROCE of -206.75%, and a year-to-date stock return of -16.05%, significantly underperforming the S&P 500.

View full answer

Is Talphera, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Talphera, Inc. shows a mildly bullish technical trend with strong short-term momentum, despite mixed signals from moving averages and a one-year underperformance compared to the S&P 500.

View full answer

Compare Talphera, Inc. with Similar Stocks

Shuttle Pharmaceuticals Holdings, Inc.Neurosense Therapeutics Ltd.Virpax Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 37 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.77

Return on Equity

-66.18%

Price to Book

1.93

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Sep 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-27.82%

6 Months

-13.43%

1 Year

26.23%

2 Years

-29.72%

3 Years

11.29%

4 Years

-87.66%

5 Years

-97.72%

Talphera, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-64.27%

EBIT Growth (5y)

11.43%

EBIT to Interest (avg)

-17.35

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.20

Sales to Capital Employed (avg)

0.03

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

30.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.93

EV to EBIT

-1.70

EV to EBITDA

-1.70

EV to Capital Employed

5.05

EV to Sales

22.15

PEG Ratio

Dividend Yield

ROCE (Latest)

-296.95%

ROE (Latest)

-66.18%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 3 Schemes (0.83%)

Foreign Institutions

Held by 4 Foreign Institutions (9.65%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -25.71% vs -29.63% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.40",
          "val2": "-3.70",
          "chgp": "8.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.10",
          "val2": "0.10",
          "chgp": "-1,200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.40",
          "val2": "-3.50",
          "chgp": "-25.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,422,000.00%",
          "val2": "0.00%",
          "chgp": "-3,42,200.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -61.11% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -26.21% vs -124.24% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.30",
          "val2": "-16.60",
          "chgp": "7.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.10",
          "chgp": "300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.00",
          "val2": "-10.30",
          "chgp": "-26.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-25,943.20%",
          "chgp": "2,594.32%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.40

-3.70

8.11%

Interest

0.00

Exceptional Items

-1.10

0.10

-1,200.00%

Consolidate Net Profit

-4.40

-3.50

-25.71%

Operating Profit Margin (Excl OI)

-3,422,000.00%

0.00%

-3,42,200.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is -25.71% vs -29.63% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

0.70

-100.00%

Operating Profit (PBDIT) excl Other Income

-15.30

-16.60

7.83%

Interest

0.40

0.10

300.00%

Exceptional Items

2.00

0.00

Consolidate Net Profit

-13.00

-10.30

-26.21%

Operating Profit Margin (Excl OI)

0.00%

-25,943.20%

2,594.32%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -61.11% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -26.21% vs -124.24% in Dec 2023

All Annual Results

Company CV

About Talphera, Inc.

Talphera, Inc.

Pharmaceuticals & Biotechnology

AcelRx Pharmaceuticals, Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidates include DSUVIA (known as DZUVEO in Europe) and Zalviso. Its DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. DSUVIA is designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with IV administration. Its Zalviso is a sufentanil sublingual tablet system intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of a pre-filled cartridge of 40 sufentanil sublingual tablets, 15 microgram (McG), delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system.

Company Coordinates

Company Details

351 Galveston Dr , REDWOOD CITY CA : 94063-4736

Tel: 1 650 2163500

http://www.acelrx.com

Registrar Details